Literature DB >> 2598414

Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models.

G F Evans1, Y M Snyder, L D Butler, S H Zuckerman.   

Abstract

Murine shock models have employed bolus endotoxin as well as cecal ligation and puncture (CLP) in an attempt to understand the pathophysiologic changes associated with human septic shock. Injection of endotoxin results in a rapid but transient rise in tumor necrosis factor (TNF), with maximal levels between 1 and 2 hr followed by an increase in serum interleukin-1 (IL-1) by 3 hr which remains elevated at 24 hr. CLP animals in contrast do not demonstrate an elevation in serum TNF, and the increase in IL-1 is less significant relative to the endotoxin model. Whereas both models demonstrate comparable increases in serum amyloid A protein and result in host death between 24 and 48 hr, these models respond differently to therapeutic modalities. Steroids and an anti-TNF monoclonal antibody administered prophylactically are effective at preventing death in the endotoxin model and yet had no beneficial effect in antibiotic-treated CLP animals. Experiments with adrenalectomized mice suggest that the absence of serum TNF in the CLP model is in part due to the modulatory effects of endogenous corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598414

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  21 in total

1.  The pulmonary inflammatory response to experimental fecal peritonitis: relative roles of tumor necrosis factor-alpha and endotoxin.

Authors:  M A Mercer-Jones; M Heinzelmann; J C Peyton; D J Wickel; M Cook; W G Cheadle
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

2.  Interleukin-10 protects against lethality of intra-abdominal infection and sepsis.

Authors:  A J Rongione; A M Kusske; K Kwan; S W Ashley; H A Reber; D W McFadden
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

3.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 4.  Modeling sepsis in the laboratory: merging sound science with animal well-being.

Authors:  Jean A Nemzek; Kelly M S Hugunin; Mark R Opp
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

5.  The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo.

Authors:  J Reckless; L M Tatalick; D J Grainger
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

6.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.

Authors:  H R Alexander; B C Sheppard; J C Jensen; H N Langstein; C M Buresh; D Venzon; E C Walker; D L Fraker; M C Stovroff; J A Norton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 7.  Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.

Authors:  J Fukata; H Imura; K Nakao
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

8.  Lipopolysaccharide-tumor necrosis factor-glucocorticoid interactions during cecal ligation and puncture-induced sepsis in mature versus senescent mice.

Authors:  S R Hyde; R E McCallum
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  Dysregulation of in vitro cytokine production by monocytes during sepsis.

Authors:  C Munoz; J Carlet; C Fitting; B Misset; J P Blériot; J M Cavaillon
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response.

Authors:  Ping Rao; Mathew S Hayden; Meixiao Long; Martin L Scott; A Philip West; Dekai Zhang; Andrea Oeckinghaus; Candace Lynch; Alexander Hoffmann; David Baltimore; Sankar Ghosh
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.